


## In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

## Listings of claims

1. (currently amended) A method of antagonising gonadotropin releasing hormone activity in a patient, comprising administering a compound of formula (I):

~~The use of a compound of Formula (I),~~




Formula (I)

wherein:


**R<sup>1</sup>** is selected from: hydrogen, optionally substituted C<sub>1-6</sub>alkyl, optionally substituted aryl or optionally substituted arylC<sub>1-6</sub>alkyl, wherein the optional substituents are selected from C<sub>1-4</sub>alkyl, nitro, cyano, fluoro and C<sub>1-4</sub>alkoxy;

**R<sup>2</sup>** is an optionally substituted mono or bi-cyclic aromatic ring, wherein the optional substituents are 1, 2 or 3 ~~substituents~~ substituents independently selected from: cyano, **R<sup>e</sup>R<sup>f</sup>N-**, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, haloC<sub>1-6</sub>alkyl or haloC<sub>1-6</sub>alkoxy wherein **R<sup>e</sup>** and **R<sup>f</sup>** are independently selected from hydrogen, C<sub>1-6</sub>alkyl or aryl;


**R<sup>3</sup>** is selected from a group of Formula (IIa) to Formula (IId):




Formula (IIa)



Formula (IIb)





Formula (IIc)



Formula (II d)

where **R<sup>6</sup>** and **R<sup>6a</sup>** are independently selected from hydrogen, fluoro, optionally substituted C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, or **R<sup>6</sup>** and **R<sup>6a</sup>** taken together and the carbon atom to which they are attached form a carbocyclic ring of 3-7 atoms or **R<sup>6</sup>** and **R<sup>6a</sup>** taken together and the carbon atom to which they are attached form a carbonyl group;

or when **A** is not a direct bond the group  forms a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms;

or the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;


**R**<sup>7</sup> is selected from: hydrogen or C<sub>1-6</sub>alkyl;


**R**<sup>8</sup> is selected from:

- (i) hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, haloC<sub>1-6</sub>alkyl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, hydroxy, hydroxyC<sub>1-6</sub>alkyl, cyano, N-C<sub>1-4</sub>alkylamino, N,N-di-C<sub>1-4</sub>alkylamino, C<sub>1-6</sub>alkyl-S(O)<sub>n</sub>-, -O-R<sup>b</sup>, -NR<sup>b</sup>R<sup>c</sup>, -C(O)-R<sup>b</sup>, -C(O)O-R<sup>b</sup>, -CONR<sup>b</sup>R<sup>c</sup>, NH-C(O)-R<sup>b</sup> or -S(O)<sub>n</sub>NR<sup>b</sup>R<sup>c</sup>,  
where **R**<sup>b</sup> and **R**<sup>c</sup> are independently selected from hydrogen and C<sub>1-6</sub>alkyl optionally substituted with hydroxy, amino, N-C<sub>1-4</sub>alkylamino, N,N-di-C<sub>1-4</sub>alkylamino, HO-C<sub>2-4</sub>alkyl-NH- or HO-C<sub>2-4</sub>alkyl-N(C<sub>1-4</sub>alkyl)-;
- (ii) nitro when **B** is a group of Formula (IV) and **X** is CH and **p** is 0;
- (iii) carbocyclyl (such as C<sub>3-7</sub>cycloalkyl or aryl) or arylC<sub>1-6</sub>alkyl each of which is optionally substituted by **R**<sup>12</sup>, or **R**<sup>13</sup>;
- (iv) heterocyclyl or heterocyclylC<sub>1-6</sub>alkyl each of which is optionally substituted by up to 4 substituents independently selected from **R**<sup>12</sup> or **R**<sup>13</sup>, and where any nitrogen atoms within a heterocyclyl group are, where chemically allowed, optionally in their oxidised (N→O, N-OH) state;

**A** is selected from:


- (i) a direct bond;
- (ii) optionally substituted C<sub>1-5</sub>alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, aryl or arylC<sub>1-6</sub>alkyl;
- (iii) a carbocyclic ring of 3-7 atoms;
- (iv) a carbonyl group or -C(O)-C(**R**<sup>d</sup>R<sup>d</sup>)-, wherein **R**<sup>d</sup> is independently selected from hydrogen and C<sub>1-2</sub>alkyl;

or when  $\mathbf{R}^3$  is a group of Formula (IIa) or (IIb), the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

or when  $\mathbf{R}^3$  is a group of Formula (IIa), (IIb), (IIc) or (IId), the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

**B** is selected from:

- (i) a direct bond;
- (ii) a group of Formula (IV)



Formula (IV)

wherein:


**X** is selected from N or CH,

wherein at position (a) Formula (IV) is attached to the nitrogen atom and the  $(\text{CH}_2)_p$  group is attached to  $\mathbf{R}^8$ ; and


- (iii) a group independently selected from: optionally substituted  $\text{C}_{1-6}$ alkylene, optionally substituted  $\text{C}_{3-7}$ cycloalkyl, optionally substituted  $\text{C}_{3-6}$ alkenylene, optionally substituted  $\text{C}_{3-6}$ alkynyl,  $(\text{C}_{1-5}\text{alkyl})_{aa}\text{-S(O}_n\text{)-(C}_{1-5}\text{alkyl})_{bb}\text{-}$ ,  $\text{-(C}_{1-5}\text{alkyl})_{aa}\text{-O-(C}_{1-5}\text{alkyl})_{bb}\text{-}$ ,  $\text{-(C}_{1-5}\text{alkyl})_{aa}\text{-C(O)-(C}_{1-5}\text{alkyl})_{bb}\text{-}$  or  $(\text{C}_{1-5}\text{alkyl})_{aa}\text{-N(R}^{17}\text{)-(C}_{1-5}\text{alkyl})_{bb}\text{-}$ , or  $\text{-(C}_{1-5}\text{alkyl})_{aa}\text{-C(O)NH-(C}_{1-5}\text{alkyl})_{bb}\text{-}$

where  $\mathbf{R}^{17}$  is hydrogen or  $\text{C}_{1-4}$ alkyl, or where  $\mathbf{R}^{17}$  and the  $(\text{C}_{1-5}\text{alkyl})_{aa}$  or  $(\text{C}_{1-5}\text{alkyl})_{bb}$  chain can be joined to form a heterocyclic ring, wherein aa and bb are independently 0 or 1 and the combined length of  $(\text{C}_{1-5}\text{alkyl})_{aa}$  and  $(\text{C}_{1-5}\text{alkyl})_{bb}$  is less than or equal to  $\text{C}_5$ alkyl and wherein the optional substituents are independently selected from  $\mathbf{R}^{12}$ ;

or the group  $\text{-B-R}^8$  represents a group of Formula (V)



Formula (V);



or the group together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from  $\mathbf{R}^{12}$  and  $\mathbf{R}^{13}$ ;




or the group forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

$\mathbf{R}^{11}$  is selected from: hydrogen, optionally substituted  $\text{C}_{1-6}$ alkyl,  $\text{N}(\mathbf{R}^{23}\mathbf{R}^{24})$  or  $\text{NC}(\text{O})\text{OR}^{25}$ , where  $\mathbf{R}^{23}$ ,  $\mathbf{R}^{24}$  and  $\mathbf{R}^{25}$  are independently selected from: hydrogen, hydroxy, optionally substituted  $\text{C}_{1-6}$ alkyl, optionally substituted aryl, optionally substituted aryl $\text{C}_{1-6}$ alkyl, an optionally substituted carbocyclic ring of 3-7 atoms, optionally substituted heterocyclyl or optionally substituted heterocyclyl $\text{C}_{1-6}$ alkyl or  $\mathbf{R}^{23}$  and  $\mathbf{R}^{24}$  taken together with the nitrogen atom to which they are attached, can form an optionally substituted ring of 3-10 atoms,

wherein the optional substituents are selected from  $\mathbf{R}^{12}$  and  $\text{---}\mathbf{K}-\mathbf{R}^8$  where K and  $\mathbf{R}^8$  are as defined herein;

**J** is a group of the formula:  $-(\text{CH}_2)_s-\mathbf{L}-(\text{CH}_2)_s-$  or  $-(\text{CH}_2)_s-\text{C}(\text{O})-(\text{CH}_2)_s-\mathbf{L}-(\text{CH}_2)_s-$  wherein when **s** is greater than 0, the alkylene group is optionally substituted,



or the group together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from  $\mathbf{R}^{12}$  and  $\mathbf{R}^{13}$ ;


**K** is selected from: a direct bond,  $-(\text{CH}_2)_{s1}-$ ,  $-(\text{CH}_2)_{s1}-\text{O}-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{C}(\text{O})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{S}(\text{O}_n)-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{N}(\mathbf{R}^{17a})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{C}(\text{O})\text{N}(\mathbf{R}^{17a})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{N}(\mathbf{R}^{17a})\text{C}(\text{O})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{N}(\mathbf{R}^{17a})\text{C}(\text{O})\text{N}(\mathbf{R}^{17a})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{OC}(\text{O})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{C}(\text{O})\text{O}-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{N}(\mathbf{R}^{17a})\text{C}(\text{O})\text{O}-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{OC}(\text{O})\text{N}(\mathbf{R}^{17a})-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{OS}(\text{O}_n)-(\text{CH}_2)_{s2}-$ , or  $-(\text{CH}_2)_{s1}-\text{S}(\text{O}_n)-\text{O}-(\text{CH}_2)_{s2}-$ ,  $-(\text{CH}_2)_{s1}-\text{S}(\text{O})_2\text{N}(\mathbf{R}^{17a})-(\text{CH}_2)_{s2}-$  or  $-(\text{CH}_2)_{s1}-\text{N}(\mathbf{R}^{17a})\text{S}(\text{O})_2-(\text{CH}_2)_{s2}-$ ; wherein the  $-(\text{CH}_2)_{s1}-$  and  $-(\text{CH}_2)_{s2}-$  groups are independently optionally substituted by hydroxy or  $\text{C}_{1-4}$ alkyl and wherein when  $s1 > 1$  or  $s2 > 1$  then the  $\text{CH}_2$  group can optionally be a branched chain.;

where  $\mathbf{R}^{17a}$  is hydrogen or  $\text{C}_{1-4}$ alkyl;

**L** is selected from optionally substituted aryl or optionally substituted heterocyclyl;

$R^4$  is selected from hydrogen,  $C_{1-4}$ alkyl or halo;

$R^5$  is selected from a group of Formula III-a; III-b; III-c; III-d; III-e; III-f, III-g, III-h, III-i, or III-j, III-k, III-l, III-m, III-n or III-o



wherein:


**het** represents an optionally substituted 3- to 8-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S, wherein the optional substituents are selected from 1-2 groups selected from  $R^{12}$  and  $R^{13}$ ; and

**Q** is selected from a direct bond or  $-[C(R^{16}R^{16a})]_{1-2}$ ;

$R^{14}$  and  $R^{15}$  are selected from:

- (i)  $R^{14}$  selected from hydrogen; optionally substituted  $C_{1-8}$ alkyl; optionally substituted aryl;  $-R^d$ -Ar, where  $R^d$  represents  $C_{1-8}$ alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and  $R^{15}$  is selected from hydrogen; optionally substituted  $C_{1-8}$ alkyl and optionally substituted aryl;

- (ii) wherein the group of Formula (III) represents a group of Formula **III-a**, **III-b**, **III-i**, **III-l** or **III-m**, then the group  $\text{NR}^{14}(-\text{R}^{15})$  represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

- (iii) wherein the group of Formula (III) represents structure **III-e**,  represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

$\text{R}^{16}$  and  $\text{R}^{16a}$  are independently selected from:

- (i) hydrogen or optionally substituted  $\text{C}_{1-6}$ alkyl; or  
(ii)  $\text{R}^{16}$  and  $\text{R}^{16a}$  together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

$\text{R}^{12}$  is independently selected from: halo, hydroxy, hydroxy $\text{C}_{1-6}$ alkyl, oxo, cyano, cyano $\text{C}_{1-6}$ alkyl, nitro, carboxyl,  $\text{C}_{1-6}$ alkyl,  $\text{C}_{1-6}$ alkoxy,  $\text{C}_{1-6}$ alkoxy $\text{C}_{1-4}$ alkyl,  $\text{C}_{1-6}$ alkoxycarbonyl $\text{C}_{0-4}$ alkyl,  $\text{C}_{1-6}$ alkanoyl $\text{C}_{0-4}$ alkyl,  $\text{C}_{1-6}$ alkanoyloxy $\text{C}_{0-4}$ alkyl,  $\text{C}_{2-6}$ alkenyl,  $\text{C}_{1-3}$ perfluoroalkyl-,  $\text{C}_{1-3}$ perfluoroalkoxy, aryl, aryl $\text{C}_{1-6}$ alkyl, heterocyclyl, heterocyclyl $\text{C}_{1-6}$ alkyl, amino $\text{C}_{0-4}$ alkyl, N- $\text{C}_{1-4}$ alkylamino $\text{C}_{0-4}$ alkyl, N, N-di- $\text{C}_{1-4}$ alkylamino $\text{C}_{0-4}$ alkyl, carbamoyl, N- $\text{C}_{1-4}$ alkylcarbamoyl $\text{C}_{0-2}$ alkyl, N, N-di- $\text{C}_{1-4}$ alkylaminocarbamoyl $\text{C}_{0-2}$ alkyl, aminocarbonyl $\text{C}_{0-4}$ alkyl, N- $\text{C}_{1-6}$ alkylaminocarbonyl $\text{C}_{0-4}$ alkyl, N, N- $\text{C}_{1-6}$ alkylaminocarbonyl $\text{C}_{0-4}$ alkyl,  $\text{C}_{1-6}$ alkyl-S(O) $_n$ -amino $\text{C}_{0-4}$ alkyl-, aryl-S(O) $_n$ -amino $\text{C}_{0-2}$ alkyl-,  $\text{C}_{1-3}$ perfluoroalkyl-S(O) $_n$ -amino $\text{C}_{0-2}$ alkyl-,  $\text{C}_{1-6}$ alkylamino-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-, arylamino-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-,  $\text{C}_{1-3}$ perfluoroalkylamino-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-,  $\text{C}_{1-6}$ alkanoylamino-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-, arylcarbonylamino-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-,  $\text{C}_{1-6}$ alkyl-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-, aryl-S(O) $_n$ - $\text{C}_{0-2}$ alkyl-,  $\text{C}_{1-3}$ perfluoroalkyl-,  $\text{C}_{1-3}$ perfluoroalkoxy $\text{C}_{0-2}$ alkyl;  $\text{R}^9\text{OC}(\text{O})(\text{CH}_2)_w$ -,  $\text{R}^{9''}\text{R}^{10''}\text{N}(\text{CH}_2)_w$ -,  $\text{R}^9\text{R}^{10'}\text{NC}(\text{O})(\text{CH}_2)_w$ -,  $\text{R}^9\text{R}^{10}\text{NC}(\text{O})\text{N}(\text{R}^9)(\text{CH}_2)_w$ -,  $\text{R}^9\text{OC}(\text{O})\text{N}(\text{R}^9)(\text{CH}_2)_w$ -, or halo, wherein  $w$  is an integer between 0 and 4 and  $\text{R}^9$  and  $\text{R}^{10}$  are independently selected from hydrogen,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{1-4}$ alkylsulphonyl and  $\text{C}_{3-7}$ carbocyclyl,  $\text{R}^{9'}$  and  $\text{R}^{10'}$  are independently selected from  $\text{C}_{1-4}$ alkylsulphonyl and  $\text{C}_{3-7}$ carbocyclyl, and  $\text{R}^{9''}$  and  $\text{R}^{10''}$  are  $\text{C}_{3-7}$ carbocyclyl; wherein an amino group within  $\text{R}^{12}$  is optionally substituted by  $\text{C}_{1-4}$ alkyl;

$\text{R}^{13}$  is  $\text{C}_{1-4}$ alkylaminocarbonyl wherein the alkyl group is optionally substituted by 1, 2 or 3 groups selected from  $\text{R}^{12}$ , or  $\text{R}^{13}$  is a group  $-\text{C}(\text{O})-\text{R}^{18}$  and  $\text{R}^{18}$  is selected from an amino acid derivative or an amide of an amino acid derivative;

**M** is selected from  $-\text{CH}_2-\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ ;

**n** is an integer from 0 to 2;

**p** is an integer from 0 to 4;

**s**, **s1** and **s2** are independently selected from an integer from 0 to 4, and

**s1+s2** is less than or equal to 4;

**t** is an integer between 0 and 4; and


or a salt, solvate or pro-drug thereof to a patient, ~~in the manufacture of a medicament for~~

~~(a) antagonising gonadotropin releasing hormone activity;~~

~~(b) administration to a patient, for reducing the secretion of luteinizing hormone by the pituitary gland of the patient; and~~

~~(c) administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.~~

2. (currently amended) A compound of formula (IA) which is a compound of formula (I) ~~as defined in claim 1;~~




Formula (I)

wherein:

**R<sup>1</sup>** is selected from: hydrogen, optionally substituted C<sub>1-6</sub>alkyl, optionally substituted aryl or optionally substituted arylC<sub>1-6</sub>alkyl, wherein the optional substituents are selected from C<sub>1-4</sub>alkyl, nitro, cyano, fluoro and C<sub>1-4</sub>alkoxy;


**R<sup>2</sup>** is an optionally substituted mono or bi-cyclic aromatic ring, wherein the optional substituents are 1, 2 or 3 substituents independently selected from: cyano, **R<sup>e</sup>R<sup>f</sup>N-**, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, haloC<sub>1-6</sub>alkyl or haloC<sub>1-6</sub>alkoxy wherein **R<sup>e</sup>** and **R<sup>f</sup>** are independently selected from hydrogen, C<sub>1-6</sub>alkyl or aryl;

**R<sup>3</sup>** is selected from a group of Formula (IIa) to Formula (IId):




Formula (IIa)


Formula (IIb)



where  $R^6$  and  $R^{6a}$  are independently selected from hydrogen, fluoro, optionally substituted  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, or  $R^6$  and  $R^{6a}$  taken together and the carbon atom to which they are attached form a carbocyclic ring of 3-7 atoms or  $R^6$  and  $R^{6a}$  taken together and the carbon atom to which they are attached form a carbonyl group;



or when **A** is not a direct bond the group forms a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms;



or the group forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

$R^7$  is selected from: hydrogen or  $C_{1-6}$ alkyl;


$R^8$  is selected from:

- (i) hydrogen,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, halo $C_{1-6}$ alkyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, hydroxy, hydroxy $C_{1-6}$ alkyl, cyano, N- $C_{1-4}$ alkylamino, N,N-di- $C_{1-4}$ alkylamino,  $C_{1-6}$ alkyl-S( $O_n$ )-, -O- $R^b$ , -NR $^b$ R $^c$ , -C(O)- $R^b$ , -C(O)O- $R^b$ , -CONR $^b$ R $^c$ , NH-C(O)- $R^b$  or -S( $O_n$ )NR $^b$ R $^c$ ,  
where  $R^b$  and  $R^c$  are independently selected from hydrogen and  $C_{1-6}$ alkyl optionally substituted with hydroxy, amino, N- $C_{1-4}$ alkylamino, N,N-di- $C_{1-4}$ alkylamino, HO- $C_{2-4}$ alkyl-NH- or HO- $C_{2-4}$ alkyl-N( $C_{1-4}$ alkyl)-;
- (ii) nitro when **B** is a group of Formula (IV) and **X** is CH and **p** is 0;
- (iii) carbocyclyl (such as  $C_{3-7}$ cycloalkyl or aryl) or aryl $C_{1-6}$ alkyl each of which is optionally substituted by  $R^{12}$ , or  $R^{13}$ ;
- (iv) heterocyclyl or heterocyclyl $C_{1-6}$ alkyl each of which is optionally substituted by up to 4 substituents independently selected from  $R^{12}$  or  $R^{13}$ , and where any nitrogen atoms within a heterocyclyl group are, where chemically allowed, optionally in their oxidised (N $\rightarrow$ O, N-OH) state;

**A** is selected from:



- (i) \_\_\_\_\_ a direct bond;
- (ii) \_\_\_\_\_ optionally substituted  $C_{1-5}$ alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxy $C_{1-6}$ alkyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, aryl or aryl $C_{1-6}$ alkyl;
- (iii) \_\_\_\_\_ a carbocyclic ring of 3-7 atoms;
- (iv) \_\_\_\_\_ a carbonyl group or  $-C(O)-C(R^dR^d)-$ , wherein  $R^d$  is independently selected from hydrogen and  $C_{1-2}$ alkyl;




or when  $R^3$  is a group of Formula (IIa) or (IIb), the group \_\_\_\_\_ forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;



or when  $R^3$  is a group of Formula (IIa), (IIb), (IIc) or (IId), the group \_\_\_\_\_ forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

**B** is selected from:

- (i) \_\_\_\_\_ a direct bond;
- (ii) \_\_\_\_\_ a group of Formula (IV)



Formula (IV)

wherein:


**X** is selected from N or CH,

wherein at position (a) Formula (IV) is attached to the nitrogen atom and the  $(CH_2)_p$  group is attached to  $R^8$ ; and


- (iii) \_\_\_\_\_ a group independently selected from: optionally substituted  $C_{1-6}$ alkylene, optionally substituted  $C_{3-7}$ cycloalkyl, optionally substituted  $C_{3-6}$ alkenylene, optionally substituted  $C_{3-6}$ alkynyl,  $(C_{1-5}alkyl)_{aa}-S(O_n)-(C_{1-5}alkyl)_{bb}-$ ,  $-(C_{1-5}alkyl)_{aa}-O-(C_{1-5}alkyl)_{bb}-$ ,  $-(C_{1-5}alkyl)_{aa}-C(O)-(C_{1-5}alkyl)_{bb}-$  or  $(C_{1-5}alkyl)_{aa}-N(R^{17})-(C_{1-5}alkyl)_{bb}-$ , or  $-(C_{1-5}alkyl)_{aa}-C(O)NH-(C_{1-5}alkyl)_{bb}-$

where  $R^{17}$  is hydrogen or  $C_{1-4}$ alkyl, or where  $R^{17}$  and the  $(C_{1-5}alkyl)_{aa}$  or  $(C_{1-5}alkyl)_{bb}$  chain can be joined to form a heterocyclic ring, wherein aa and bb are independently 0 or 1


and the combined length of (C<sub>1-5</sub>alkyl)<sub>aa</sub> and (C<sub>1-5</sub>alkyl)<sub>bb</sub> is less than or equal to C<sub>5</sub>alkyl  
 and wherein the optional substituents are independently selected from **R**<sup>12</sup>;  
 or the group –**B-R**<sup>8</sup> represents a group of Formula (V)



Formula (V);




or the group together forms an optionally substituted heterocyclic ring  
 containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or  
 2 substituents independently selected from **R**<sup>12</sup> and **R**<sup>13</sup>;




or the group forms a heterocyclic ring containing 3-7 carbon atoms and  
 one or more heteroatoms;

**R**<sup>11</sup> is selected from: hydrogen, optionally substituted C<sub>1-6</sub>alkyl, N(**R**<sup>23</sup>**R**<sup>24</sup>) or NC(O)OR<sup>25</sup>,  
 where **R**<sup>23</sup>, **R**<sup>24</sup> and **R**<sup>25</sup> are independently selected from: hydrogen, hydroxy, optionally  
 substituted C<sub>1-6</sub>alkyl, optionally substituted aryl, optionally substituted arylC<sub>1-6</sub>alkyl, an  
 optionally substituted carbocyclic ring of 3-7 atoms, optionally substituted heterocyclyl or  
 optionally substituted heterocyclylC<sub>1-6</sub>alkyl or **R**<sup>23</sup> and **R**<sup>24</sup> taken together with the nitrogen  
 atom to which they are attached, can form an optionally substituted ring of 3-10 atoms,

wherein the optional substituents are selected from **R**<sup>12</sup> and  where K and **R**<sup>8</sup> are  
 as defined herein;

**J** is a group of the formula: -(CH<sub>2</sub>)<sub>s</sub>-**L**-(CH<sub>2</sub>)<sub>s</sub>- or -(CH<sub>2</sub>)<sub>s</sub>-C(O)-(CH<sub>2</sub>)<sub>s</sub>-**L**-(CH<sub>2</sub>)<sub>s</sub>-wherein  
 when **s** is greater than 0, the alkylene group is optionally substituted,



or the group together forms an optionally substituted heterocyclic ring  
 containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2  
 substituents independently selected from **R**<sup>12</sup> and **R**<sup>13</sup>;

**K** is selected from: a direct bond, -(CH<sub>2</sub>)<sub>s1</sub>-, -(CH<sub>2</sub>)<sub>s1</sub>-O-(CH<sub>2</sub>)<sub>s2</sub>-, -(CH<sub>2</sub>)<sub>s1</sub>-C(O)-(CH<sub>2</sub>)<sub>s2</sub>-,  
 -(CH<sub>2</sub>)<sub>s1</sub>-S(O<sub>n</sub>)-(CH<sub>2</sub>)<sub>s2</sub>-, -(CH<sub>2</sub>)<sub>s1</sub>-N(**R**<sup>17a</sup>)-(CH<sub>2</sub>)<sub>s2</sub>-, -(CH<sub>2</sub>)<sub>s1</sub>-C(O)N(**R**<sup>17a</sup>)-(CH<sub>2</sub>)<sub>s2</sub>-,  
 -(CH<sub>2</sub>)<sub>s1</sub>-N(**R**<sup>17a</sup>)C(O)-(CH<sub>2</sub>)<sub>s2</sub>-, -(CH<sub>2</sub>)<sub>s1</sub>-N(**R**<sup>17a</sup>)C(O)N(**R**<sup>17a</sup>)-(CH<sub>2</sub>)<sub>s2</sub>-, -(CH<sub>2</sub>)<sub>s1</sub>-OC(O)-(CH<sub>2</sub>)<sub>s2</sub>-.


$-(CH_2)_{s1}-C(O)O-(CH_2)_{s2}-$ ,  $-(CH_2)_{s1}-N(R^{17a})C(O)O-(CH_2)_{s2}-$ ,  $-(CH_2)_{s1}-OC(O)N(R^{17a})-(CH_2)_{s2}-$ ,  $-(CH_2)_{s1}-OS(O)_n-(CH_2)_{s2}-$ , or  $-(CH_2)_{s1}-S(O)_n-O-(CH_2)_{s2}-$ ,  $-(CH_2)_{s1}-S(O)_2N(R^{17a})-(CH_2)_{s2}-$  or  $-(CH_2)_{s1}-N(R^{17a})S(O)_2-(CH_2)_{s2}-$ ; wherein the  $-(CH_2)_{s1}-$  and  $-(CH_2)_{s2}-$  groups are independently optionally substituted by hydroxy or  $C_{1-4}$ alkyl and wherein when  $s1 > 1$  or  $s2 > 1$  then the  $CH_2$  group can optionally be a branched chain.;

where  $R^{17a}$  is hydrogen or  $C_{1-4}$ alkyl;

**L** is selected from optionally substituted aryl or optionally substituted heterocyclyl;

$R^4$  is selected from hydrogen,  $C_{1-4}$ alkyl or halo;

$R^5$  is selected from a group of Formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**; **III-g**; **III-h**; **III-i**; or **III-j**, **III-k**, **III-l**, **III-m**, **III-n** or **III-o**



wherein:

**het** represents an optionally substituted 3- to 8-membered heterocyclic ring


containing from 1 to 4 heteroatoms independently selected from O, N and S,

wherein the optional substituents are selected from 1-2 groups selected from  $R^{12}$  and  $R^{13}$ ; and

**Q** is selected from a direct bond or  $-[C(R^{16}R^{16a})]_{1-2}-$ .

**R<sup>14</sup>** and **R<sup>15</sup>** are selected from:

- (i) **R<sup>14</sup>** selected from hydrogen; optionally substituted C<sub>1-8</sub>alkyl; optionally substituted aryl; -**R<sup>d</sup>**-Ar, where **R<sup>d</sup>** represents C<sub>1-8</sub>alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and **R<sup>15</sup>** is selected from hydrogen; optionally substituted C<sub>1-8</sub>alkyl and optionally substituted aryl;
- (ii) wherein the group of Formula (III) represents a group of Formula **III-a**, **III-b**, **III-i**, **III-l** or **III-m**, then the group **NR<sup>14</sup>**(-**R<sup>15</sup>**) represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or



- (iii) wherein the group of Formula (III) represents structure **III-e**, represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

**R<sup>16</sup>** and **R<sup>16a</sup>** are independently selected from:

- (i) hydrogen or optionally substituted C<sub>1-8</sub>alkyl; or
- (ii) **R<sup>16</sup>** and **R<sup>16a</sup>** together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

**R<sup>12</sup>** is independently selected from: halo, hydroxy, hydroxyC<sub>1-6</sub>alkyl, oxo, cyano, cyanoC<sub>1-6</sub>alkyl, nitro, carboxyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkoxyC<sub>1-4</sub>alkyl, C<sub>1-6</sub>alkoxycarbonylC<sub>0-4</sub>alkyl, C<sub>1-6</sub>alkanoylC<sub>0-4</sub>alkyl, C<sub>1-6</sub>alkanoyloxyC<sub>0-4</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>1-3</sub>perfluoroalkyl-, C<sub>1-3</sub>perfluoroalkoxy, aryl, arylC<sub>1-6</sub>alkyl, heterocyclyl, heterocyclylC<sub>1-6</sub>alkyl, aminoC<sub>0-4</sub>alkyl, **N**-C<sub>1-4</sub>alkylaminoC<sub>0-4</sub>alkyl, **N**, **N**-di-C<sub>1-4</sub>alkylaminoC<sub>0-4</sub>alkyl, carbamoyl, **N**-C<sub>1-4</sub>alkylcarbamoylC<sub>0-2</sub>alkyl, **N**, **N**-di-C<sub>1-4</sub>alkylaminocarbamoylC<sub>0-2</sub>alkyl, aminocarbonylC<sub>0-4</sub>alkyl, **N**-C<sub>1-6</sub>alkylaminocarbonylC<sub>0-4</sub>alkyl, **N**, **N**-C<sub>1-6</sub>alkylaminocarbonylC<sub>0-4</sub>alkyl, C<sub>1-6</sub>alkyl-S(O)<sub>n</sub>-aminoC<sub>0-4</sub>alkyl-, aryl-S(O)<sub>n</sub>-aminoC<sub>0-2</sub>alkyl-, C<sub>1-3</sub>perfluoroalkyl-S(O)<sub>n</sub>-aminoC<sub>0-2</sub>alkyl-, C<sub>1-6</sub>alkylamino-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, arylamino-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, C<sub>1-3</sub>perfluoroalkylamino-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, C<sub>1-6</sub>alkanoylamino-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, arylcarbonylamino-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, C<sub>1-6</sub>alkyl-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, aryl-S(O)<sub>n</sub>-C<sub>0-2</sub>alkyl-, C<sub>1-3</sub>perfluoroalkyl-, C<sub>1-3</sub>perfluoroalkoxyC<sub>0-2</sub>alkyl; **R<sup>9</sup>**OC(O)(CH<sub>2</sub>)<sub>w</sub>-, **R<sup>9</sup>****R<sup>10</sup>**N(CH<sub>2</sub>)<sub>w</sub>-, **R<sup>9</sup>****R<sup>10</sup>**NC(O)(CH<sub>2</sub>)<sub>w</sub>-, **R<sup>9</sup>****R<sup>10</sup>**NC(O)N(**R<sup>9</sup>**)(CH<sub>2</sub>)<sub>w</sub>-, **R<sup>9</sup>**OC(O)N(**R<sup>9</sup>**)(CH<sub>2</sub>)<sub>w</sub>-, or halo, wherein **w** is an integer between 0 and 4 and **R<sup>9</sup>** and **R<sup>10</sup>** are independently selected from hydrogen, C<sub>1-4</sub>alkyl,

C<sub>1-4</sub>alkylsulphonyl and C<sub>3-7</sub>carbocyclyl, R<sup>9'</sup> and R<sup>10'</sup> are independently selected from C<sub>1-4</sub>alkylsulphonyl and C<sub>3-7</sub>carbocyclyl, and R<sup>9''</sup> and R<sup>10''</sup> are C<sub>3-7</sub>carbocyclyl; wherein an amino group within R<sup>12</sup> is optionally substituted by C<sub>1-4</sub>alkyl;

R<sup>13</sup> is C<sub>1-4</sub>alkylaminocarbonyl wherein the alkyl group is optionally substituted by 1, 2 or 3 groups selected from R<sup>12</sup>, or R<sup>13</sup> is a group -C(O)-R<sup>18</sup> and R<sup>18</sup> is selected from an amino acid derivative or an amide of an amino acid derivative;

M is selected from -CH<sub>2</sub>-CH<sub>2</sub>- or -CH=CH-;

n is an integer from 0 to 2;

p is an integer from 0 to 4;


s, s1 and s2 are independently selected from an integer from 0 to 4, and


s1+s2 is less than or equal to 4;


t is an integer between 0 and 4; and


or a salt, solvate or pro-drug thereof;

with the proviso that when


- (i) the group  forms an aromatic carbocyclic ring of 3-7 carbon atoms or an aromatic heterocyclic ring containing one or more heteroatoms, or

- (ii) when R<sup>3</sup> is a group of Formula (IIa) or (IIb), and the group  forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or
- (iii) when R<sup>3</sup> is a group of Formula (IIa), (IIb), (IIc) or (IIId), and the group

-  forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms, or


- (iv) when the group  forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms and A is a direct bond;
- then R<sup>5</sup> is other than a group III-o.

3. (original) A compound according to claim 2 wherein the group **A** is selected from (i) a direct bond or (ii) optionally substituted C<sub>1-5</sub>alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, aryl or arylC<sub>1-6</sub>alkyl.
4. (currently amended) A compound according to claim 2 ~~or claim 3~~ which includes a group **R**<sup>13</sup> and wherein the group **R**<sup>13</sup> is -C(O)-**R**<sup>18</sup>, and **R**<sup>18</sup> is selected from an amino acid derivative or an amide of an amino acid derivative; or a salt, solvate or pro-drug thereof.
5. (currently amended) A compound according to claim 2 ~~any one of claims 2 to 4~~ wherein **R**<sup>1</sup> is selected from hydrogen, optionally substituted C<sub>1-6</sub>alkyl or optionally substituted arylC<sub>1-6</sub>alkyl, wherein the optional substituents ~~substituents~~ are selected from: fluoro and C<sub>1-4</sub>alkoxy.
6. (currently amended) A compound according to claim 2 ~~any one of claims 2 to 5~~ wherein **R**<sup>2</sup> is phenyl, optionally substituted ~~substituted~~ by one or more groups selected from methyl, ethyl, methoxy, ethoxy, *tert*-butoxy, F or Cl.
7. (currently amended) A compound according to claim 2 ~~any one of claims 2 to 6~~ wherein **R**<sup>3</sup> is selected from a group of formula (IIc) or formula (IId).
8. (currently amended) A compound according to claim 2 ~~any one of claims 2 to 7~~ wherein **R**<sup>4</sup> is selected from hydrogen, methyl, ethyl, chloro or bromo.
9. (currently amended) A compound according to claim 2 ~~any one of claims 2 to 8~~ wherein **R**<sup>5</sup> is selected from a group of Formula III-a , III-g, III-h, III-i, III-j, III-k, III-l: or III-o




wherein **R**<sup>16</sup>, **R**<sup>16a</sup>, **R**<sup>14</sup> and **R**<sup>15</sup> are as defined in claim 2[[1]].

10. (original) A compound according to claim 9 wherein  $R^5$  is a group of formula



11. (currently amended) A compound according to claim 2 ~~any one of claims 2 to 10~~ wherein **M** is  $-\text{CH}_2-\text{CH}_2-$ .


12. (currently amended) A compound of Formula (Ia) as claimed in claim 2




Formula (Ia)

wherein:

$R^3$  is selected from a group of Formula (IIa) or Formula (IIb):




Formula (IIa)



Formula (IIb)

$R^7$  is selected from: hydrogen or  $\text{C}_{1-6}$ alkyl;

**B** is a group of Formula (IV)




Formula (IV)

and  $p$ , **A**, **X**, **M**,  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^8$ , and  $R^{11}$  are as defined in claim 2 ~~above for a compound of Formula (I)~~

or a salt, solvate or pro-drug thereof.


13. (currently amended) A compound of Formula (Ic) which is a compound of formula (Ia) as claimed in claim 2 wherein:




Formula (Ic)

wherein:

$R^3$  is selected from a group of Formula (IIc) or Formula (IId):




Formula (IIc)



Formula (IId)

wherein



the group together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from  $R^{12}$  and  $R^{13}$ ;

and **A**, **M**, **J**,  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^8$ , and  $R^{12}$  and  $R^{13}$  are as defined in claim 2[[1]], or a salt, solvate or pro-drug thereof.

14. (currently amended) A compound selected from:

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(morpholin-4-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)but-2-en-1-yl]-4-

[1s-methyl-2-(n'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;



3-[3,3-dimethylDimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-dimethylDimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

2-chloro-3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(4-hydroxypiperidin-1-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(1,1-dioxo-isothiazolidin-2-ylcarbonyl)-4-methoxy-piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{1-benzyl-pyrroldin-3-ylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-(2-{4-n-isopropylureidophenyl}ethylamino)ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;


3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-(pyrid-4-yl)piperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{3-(pyrid-4-yl)ppyrrolidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole; and


3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-phenylpiperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole.

15. (currently amended) A process for preparing a compound of formula (I) as defined in claim 2 1, ~~or a compound according to any one of claims 2 to 14~~, said process comprising a step selected from (a) to (h):


(a) reaction of a compound of formula **XXXII** with a compound of formula  $H-R^3$ ,



**XXXII**




wherein  $\mathbf{X}^1$  is selected from: ;  $\mathbf{L}^1$  is a displaceable group; and




$\mathbf{H-R}^{3'}$  is selected from:

- (b) reaction of a compound of formula **XXXIII** with a compound of formula  $\mathbf{L}^2\text{-R}^{3''}$ ,



**XXXIII**



wherein  $\mathbf{X}^2$  is selected from: ;  $\mathbf{L}^2$  is a displaceable group and  $\mathbf{R}^{7a}$  is selected from the definition of  $\mathbf{R}^7$  or  $\mathbf{R}^{22}$  above, and


$\mathbf{L}^2\text{-R}^{3''}$  is selected from:  $\mathbf{L}^2\text{-B-R}^8$  ,  $\mathbf{L}^2\text{-J-K-R}^8$  and  $\mathbf{L}^2\text{-R}^{21}$

- (c) for compounds of Formula (I) or (IA) wherein  $\mathbf{R}^7$  is other than part of a heterocyclic ring or hydrogen, reaction of a compound of Formula (I) or (IA) wherein  $\mathbf{R}^3$  is a group of Formula (IIa), (IIb), (IIc) or (IId) and  $\mathbf{R}^7$  is hydrogen with a group of formula  $\mathbf{L}^3\text{-R}^{7a}$ , wherein  $\mathbf{R}^{7a}$  is as defined above for  $\mathbf{R}^7$  with the exclusion of hydrogen and  $\mathbf{L}^3$  is a displaceable group;
- (d) for compounds of Formula (I) or (IA) wherein  $\mathbf{R}^4$  is hydrogen, reduction of a thienopyrrole of Formula **XXXVII**





**XXXVII**



- (e) for compounds of Formula (I) wherein  $\mathbf{R}^3$  is a group of Formula (IIc) or (IId) and



the group together forms an optionally substituted nitrogen-containing heterocyclic ring containing 4-7 carbons atoms, reaction of a compound of Formula **XXXIVa** or **XXXIVb**, with a compound of Formula **L<sup>6</sup>-K-R<sup>8</sup>**, wherein **L<sup>6</sup>** is a displaceable group


**XXXIVa****XXXIVb**

- (f) for compounds of Formula (I) wherein **R<sup>3</sup>** is a group of Formula (IIc) or (IId), reaction of a compound of Formula **XXXVa** or **XXXVb**, with a compound of Formula **L<sup>7</sup>-K''-R<sup>8</sup>**, wherein **L<sup>7</sup>** is a displaceable group, and wherein the groups **K'** and **K''** comprise groups which when reacted together form **K**,


**XXXVa****XXXVb**

;

- (g) reaction of a compound of Formula **XXXVI** with an electrophilic compound of the formula **L<sup>8</sup>-R<sup>3</sup>**, wherein **L<sup>8</sup>** is a displaceable group

**XXXVI**

- (h) reaction of a compound of Formula XXXIX with an appropriate electrophilic reagent to give a compounds of Formula (I)



**XXXIX**

and thereafter if necessary, carrying out one or more of the following steps:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.

16. (currently amended) A pharmaceutical formulation comprising a compound according to claim 2 ~~any one of claims 2 to 14~~, or salt, pro-drug or solvate thereof, and a pharmaceutically acceptable diluent or carrier.

17-18. (cancelled)